Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient

J Crohns Colitis. 2015 Sep;9(9):816-7. doi: 10.1093/ecco-jcc/jjv109. Epub 2015 Jun 12.
No abstract available

Keywords: Crohn’s disease; anti-TNFα; orthotopic liver transplant; ustekinumab.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Certolizumab Pegol / therapeutic use
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Drug Administration Schedule
  • Humans
  • Infliximab / therapeutic use
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / surgery*
  • Liver Transplantation*
  • Male
  • Ustekinumab / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Infliximab
  • Ustekinumab
  • Adalimumab
  • Certolizumab Pegol